Trial reportBMC oral health2020
Effects of probiotic bacterium Weissella cibaria CMU on periodontal health and microbiota: a randomised, double-blind, placebo-controlled trial.
Trial report in BMC oral health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Efficacy of Probiotic Consumption on Oral Outcomes in Children and/or Adolescents: A Meta-Analysis.International dental journal · 2024Pooled it
- Trial
- A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Acidogenic Potential of Dental Biofilms through a Tablet ContainingInternational journal of environmental research and public health · 2021Trial
- Combination of Lacticaseibacillus rhamnosus and Weissella confusa treatment improves ligature-induced periodontitis in rats via immune modulation and inhibition of oral pathogens.BMC oral health · 2026Article
- First characterization of the oral microbiota of capybaras (Hydrochoerus hydrochaeris) in Brazil: insights into one health risks.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Microbiota and quality profiling of fermented goat meat sausages (sucuk) under nitrite-reduced and mixed-culture strategies.World journal of microbiology & biotechnology · 2026Article
- Transition of oral microbiome profile in HIV-infected Indonesian patients: the role of antiretroviral therapy.Journal of oral microbiology · 2026Article
- Review
- The Effect ofMicroorganisms · 2025Article
- Probiotics and Oral Complications of Antineoplastic Therapy in Head and Neck Cancer: A Systematic Review and Meta-Analysis.Dentistry journal · 2025Review
- A one-two punch of inflammation and oxidative stress promotes revascularization for diabetic foot ulcers.Materials today. Bio · 2025Article
- In Vitro Effects ofJournal of functional biomaterials · 2024Article
- The anticancer mechanisms of exopolysaccharide from Weissella cibaria D-2 on colorectal cancer via apoptosis induction.Scientific reports · 2023Article
- The Benefits of Probiotics on Oral Health: Systematic Review of the Literature.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Differentiation betweenInternational journal of molecular sciences · 2023Article
- In Vitro Preventive Effect and Mechanism of Action ofMicroorganisms · 2023Article
- Improvement of halitosis by probiotic bacteriumFrontiers in microbiology · 2023Article
- Potential oral probiotic Lactobacillus pentosus MJM60383 inhibits Streptococcus mutans biofilm formation by inhibiting sucrose decomposition.Journal of oral microbiology · 2023Article
- TheFrontiers in microbiology · 2023Review
- Toxicological and safety evaluations ofToxicological research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundWeissella cibaria CMU (oraCMU) has been commercially available in the market for several years as oral care probiotics. The present study aimed to evaluate the effects of oraCMU-containing tablets on periodontal health and oral microbiota.
methodsA randomised, double-blind, placebo-controlled trial was conducted in 92 adults without periodontitis (20-39 years of age). All subjects received dental scaling and root planing, and were randomly assigned to either probiotic or placebo groups. The tablets were administered once daily for 8 weeks. Periodontal clinical parameters included bleeding on probing (BOP), probing depth (PD), gingival index (GI), and plaque index (PI). In addition, microbiota in the gingival sulcus were analysed.
resultsBOP improved more in the probiotic group over 8 weeks. There were statistically significant differences in BOP of the maxilla buccal and lingual sites between the groups during the intervention (P < 0.05). No significant inter-group differences in PD, GI, and PI were observed during the intervention. Oral bacteria were observed to be fewer in the probiotic group. There was a significant change in levels of Fusobacterium nucleatum at four and 8 weeks between the two groups. Besides, there were significant differences at 8 weeks in levels of Staphylococcus aureus.
conclusionsWe reported an improvement in BOP and microbial environment and demonstrated the antimicrobial activity of oraCMU against F. nucleatum. Thus, its supplementation may contribute to overall oral health.
trial registrationEthical issues approved by the Kangwon National University Institutional Review Board with a number of KWNUIRB-2018-05-003-005 and CRIS code Number of KCT0005078 were retrospectively registered on 06/02/2020. This study was conducted in the period of July to November 2018.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.